[go: up one dir, main page]

AU2003287666A1 - Systemic delivery of antiviral agents - Google Patents

Systemic delivery of antiviral agents

Info

Publication number
AU2003287666A1
AU2003287666A1 AU2003287666A AU2003287666A AU2003287666A1 AU 2003287666 A1 AU2003287666 A1 AU 2003287666A1 AU 2003287666 A AU2003287666 A AU 2003287666A AU 2003287666 A AU2003287666 A AU 2003287666A AU 2003287666 A1 AU2003287666 A1 AU 2003287666A1
Authority
AU
Australia
Prior art keywords
antiviral agents
systemic delivery
systemic
delivery
antiviral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003287666A
Other languages
English (en)
Other versions
AU2003287666A8 (en
Inventor
Paul Ashton
Jianbing Chen
Thomas J. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Control Delivery Systems Inc
Original Assignee
Control Delivery Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Systems Inc filed Critical Control Delivery Systems Inc
Publication of AU2003287666A8 publication Critical patent/AU2003287666A8/xx
Publication of AU2003287666A1 publication Critical patent/AU2003287666A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003287666A 2002-11-13 2003-11-13 Systemic delivery of antiviral agents Abandoned AU2003287666A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42594302P 2002-11-13 2002-11-13
US60/425,943 2002-11-13
PCT/US2003/036637 WO2004043435A2 (fr) 2002-11-13 2003-11-13 Administration systemique d'agents antiviraux

Publications (2)

Publication Number Publication Date
AU2003287666A8 AU2003287666A8 (en) 2004-06-03
AU2003287666A1 true AU2003287666A1 (en) 2004-06-03

Family

ID=32313080

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003287666A Abandoned AU2003287666A1 (en) 2002-11-13 2003-11-13 Systemic delivery of antiviral agents

Country Status (2)

Country Link
AU (1) AU2003287666A1 (fr)
WO (1) WO2004043435A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
AU2008262031B2 (en) 2007-06-08 2011-08-25 Boehringer Ingelheim International Gmbh Extended release formulation of nevirapine
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
EP3412260B1 (fr) 2009-05-18 2020-08-26 Dose Medical Corporation Implant oculaire à élution de médicament
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20110238036A1 (en) * 2009-12-23 2011-09-29 Psivida Us, Inc. Sustained release delivery devices
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
MX2016014622A (es) * 2014-05-30 2017-05-04 Textile-Based Delivery Inc Sistemas de suministro de medicamentos y metodos de uso relacionados.
CA3003397A1 (fr) 2014-10-30 2016-05-06 Textile-Based Delivery, Inc. Systemes d'administration
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (fr) 2015-09-25 2017-03-30 Glaukos Corporation Implants lacrymaux à caractéristiques d'administration de médicament régulée et leurs procédés d'utilisation
WO2017184881A1 (fr) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Dispositif d'administration de médicament oculaire biorésorbable
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US6039975A (en) * 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices

Also Published As

Publication number Publication date
AU2003287666A8 (en) 2004-06-03
WO2004043435A2 (fr) 2004-05-27
WO2004043435A3 (fr) 2004-07-08

Similar Documents

Publication Publication Date Title
AU2003251323A1 (en) Delivery devices
AU2002322719A1 (en) Delivery of therapeutic capable agents
AU2003287666A1 (en) Systemic delivery of antiviral agents
AU2003298738A1 (en) Liposomal formulations
AU2003224725A1 (en) Hiv therapeutic
EP1562557B8 (fr) Vehicules pour administration de geodats
AU2003211103A1 (en) Intracellular delivery of therapeutic agents
AU2002364893A1 (en) Delivery of medicaments to the nail
AU2003274355A1 (en) Targeted delivery
AU2003220968A1 (en) Anti-inflammatory agent
AU2003231947A1 (en) Defensins: use as antiviral agents
AU2003273819A1 (en) Coating agent
AU2002353510A1 (en) Nebuliser
AU2003292859A1 (en) Feng-you-jing spray
AU2002240942A1 (en) Improved delivery of benefit agents
AU2003289207A1 (en) Anti-inflammatory agent
AU2003290818A1 (en) Topoisomerase-targeting agents
AU2003273803A1 (en) Use of triptans as antiviral agents
AU2002222557A1 (en) Interferon therapeutic effect-potentiating agents
AU2003296961A1 (en) Targeted invitation delivery
AU2003207181A1 (en) Microorganism-trapping agent
AU2003269950A1 (en) Heteroaryl-ethanolamine derivatives as antiviral agents
AU2003304151A1 (en) Heteroaryl-ethanolamine derivatives as antiviral agents
AU2003252311A1 (en) Bubble-diffusing nozzle
AU2003265385A1 (en) Aryl-ethanolamine derivatives as antiviral agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase